Login to Your Account

Clinic Roundup

Wednesday, October 12, 2011
Pevion Biotech AG, of Bern, Switzerland, reported the latest results from its ongoing clinical study of volunteers vaccinated with the intramuscular high dose of Candida vaccine PEV7, showing high levels of specific antibodies and a 100 percent mucosal immune response rate. Data showed significantly increased immunogenicity over the previously vaccinated low-dose group and confirmed the safety profile customary for virosome-delivered vaccines.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription